Whether a stock needs to stay or go requires holistic evaluation, not just short-term comparisons to the S&P 500.

As funding constraints and shifting investment priorities reshape the CGT landscape, the importance of building resilient, collaborative frameworks is evident.

Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making. BioMarin’s acquisition of Amicus ...

Cash Burn -- $50.2 million in 2025, an improvement from $57.8 million in 2024 due to lower headcount and development costs.

Explore what is driving progress in neurological biomarker research today, from emerging technologies to clinical translation ...

Since its founding in 1995, the Contra the Heard investment newsletter has been providing subscribers with thoroughly researched stock picks that all have one thing in common: a strong, data-driven ...

Discover how women can build smarter investment portfolios that match real-life goals, caregiving demands, career breaks, and longer retirement timelines.

The DNA foundation model Evo 2 has been published in the journal Nature. Trained on the DNA of over 100,000 species across ...

Former OpenAI researcher Leopold Aschenbrenner has grown Situational Awareness LP from $383 million to $5.52 billion in under ...

A common pitfall in digital healthcare is treating data governance as a secondary compliance task rather than a foundational ...

Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes ...

Recent advancements in systems biology have been propelled by the increasing power of omics technologies—spanning genomics, transcriptomics, proteomics, ...